Stockysis — AI-Powered Stock News & Sentiment Analysis

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.7%

Neg 0% Neu 89.7% Pos 0%

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.

Comments

No comments yet. Be the first!